PRKCB and B-cell chronic lymphocytic leukemia: This mechanism is likely to involve active PKCβII because of our previous work demonstrating that pretreatment of CLL cells with LY379196, a PKCβ-specific inhibitor48, blocks the effects of VEGF24.